{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/angina/management/new-diagnosis/","result":{"pageContext":{"chapter":{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis","depth":2,"htmlHeader":"<!-- begin field 8fc88aab-c63b-4876-84c0-f79a46106860 --><h2>Scenario: New diagnosis</h2><!-- end field 8fc88aab-c63b-4876-84c0-f79a46106860 -->","summary":"Covers the management of people with a newly-confirmed diagnosis of stable angina.","htmlStringContent":"<!-- begin item 2a677fe3-e504-43ba-8546-273375d8e037 --><!-- begin field be41c930-3ebf-4869-818e-acbd00860ff6 --><p>From age 16 years onwards.</p><!-- end field be41c930-3ebf-4869-818e-acbd00860ff6 --><!-- end item 2a677fe3-e504-43ba-8546-273375d8e037 -->","topic":{"id":"24c3b3ba-4467-513f-abfe-8ce9696ebacf","topicId":"b8a92113-15ce-47f8-b5f2-29135fbaeb9a","topicName":"Angina","slug":"angina","lastRevised":"Last revised in November 2020","chapters":[{"id":"d037d955-219a-51cb-9b7b-d80e4698480c","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"5b576d3c-d1ef-5582-9049-3daf9166c674","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cf8d028-1d6d-5b17-9009-24daa603c2ad","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"a6e68c4e-737d-529e-9f2e-1d371564e243","slug":"changes","fullItemName":"Changes"},{"id":"8b294548-958c-5d4a-994a-d658b034e0ed","slug":"update","fullItemName":"Update"}]},{"id":"c182c0dc-2d1c-56e3-9ddf-42e6c9141f36","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"1551834c-ae66-5b2c-84f5-a2d776dc7567","slug":"goals","fullItemName":"Goals"},{"id":"b81e978d-4230-5023-bc0d-fb2d054d74aa","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"3c2825f8-cb3b-5b34-9ebb-b3a46c766ad4","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6995e8ae-daff-5a5e-a996-7bdceeea4732","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"ce74d231-e2d6-56f8-ac25-96c7241244cc","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"472866af-8514-57e4-b1d5-e76616c0e906","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"891abedd-d2c4-5a34-8cb6-b56547b6ba9b","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"122479e4-f056-5d94-8c91-9b335aabc39c","slug":"definition","fullItemName":"Definition"},{"id":"7602d977-de51-5c3e-ba00-039a782195fe","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"c395652b-1917-588c-844c-c3d57cfce9ec","slug":"complications","fullItemName":"Complications"},{"id":"6afa1096-05eb-5cd0-9f06-d62a61ee26eb","slug":"prognosis","fullItemName":"Prognosis"},{"id":"0b84b71b-1d99-58d0-a7ba-5bdb9b3f6bd2","slug":"prevalence","fullItemName":"Prevalence"}]},{"id":"77a23b35-11f3-574c-b4c0-818798961d36","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"1c414f08-80ea-5957-8637-b7691da3f4ba","slug":"assessment-of-stable-chest-pain","fullItemName":"Assessment of stable chest pain"},{"id":"aa7c3bff-512c-5ada-919e-f74c0d819710","slug":"confirming-the-diagnosis","fullItemName":"Confirming the diagnosis"},{"id":"7a2866dc-7796-52e4-859a-a7d02908df33","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"9f5fa5d2-ae88-5bdd-892e-f0bc8348f1a8","slug":"awaiting-diagnostic-testing","fullItemName":"Awaiting diagnostic testing"}]},{"id":"bc614509-86f3-56fe-baa9-015bad71459b","fullItemName":"Management","slug":"management","subChapters":[{"id":"97e1a557-e962-51f0-9fd2-26ed6d619574","slug":"new-diagnosis","fullItemName":"Scenario: New diagnosis"},{"id":"244b2360-1f5d-5f3e-8685-b041b97398d3","slug":"routine-review","fullItemName":"Scenario: Routine review"},{"id":"ef455505-25b3-57d4-851c-8db39de1ca9f","slug":"poor-control-on-treatment","fullItemName":"Scenario: Poor control on treatment"}]},{"id":"d18ef561-191a-5df7-a1f7-ef2d79106a0d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"813aebe7-14a8-557c-bac0-87a6cfe91c34","slug":"nitrates","fullItemName":"Nitrates"},{"id":"a1a4269f-60e8-5f82-938f-f4224de056ff","slug":"ivabradine","fullItemName":"Ivabradine"},{"id":"b276b003-d2f8-5a9d-ab8e-71924285102d","slug":"calcium-channel-blockers","fullItemName":"Calcium-channel blockers"},{"id":"e5a32575-7219-5c2f-b008-229c08a61dd5","slug":"ranolazine","fullItemName":"Ranolazine"},{"id":"ec1ac1aa-2520-5cda-877d-07f3ed8d3453","slug":"beta-blockers","fullItemName":"Beta-blockers"},{"id":"7261389f-2f16-563e-96b2-2543a8a4ee17","slug":"nicorandil","fullItemName":"Nicorandil"}]},{"id":"11c1f888-ca90-5be7-a7a1-2c8d7b44961c","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"3669e04b-2ce6-595d-b4cb-e5abcb213a1e","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"283f72a3-a414-5e7f-9f58-d86340ba7348","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"58238f70-829d-5fd5-bea6-4b71b01a6633","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"985e0900-f162-5892-a6ae-ee6a677babb1","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d892adf9-3736-5e8b-a845-d4cb6ce084b7","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"c0c74471-a5d7-52eb-bf37-6b038917dce3","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"157e1fd8-63b8-5cc6-a4ad-44ae83612fe9","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"bc614509-86f3-56fe-baa9-015bad71459b","slug":"management","fullItemName":"Management"},"subChapters":[{"id":"9c0f1382-1d39-5298-aaf1-916b33102b55","slug":"patient-information-support","fullItemName":"Patient information and support","depth":3,"htmlHeader":"<!-- begin field a2be4ee9-8a59-4202-85ff-21b26afc37c7 --><h3>What information and support should I provide for a person with stable angina?</h3><!-- end field a2be4ee9-8a59-4202-85ff-21b26afc37c7 -->","summary":null,"htmlStringContent":"<!-- begin item cd656055-1c39-4b07-a1c7-2ba25e28af4b --><!-- begin field 63210e39-f9a0-4622-ba88-8fec016fc719 --><ul><li><strong>Provide information and support for people with newly diagnosed angina.</strong><ul><li>Clearly explain the diagnosis of stable angina to the person. The explanation should include:<ul><li>Factors that can provoke angina, such as exertion, emotional stress, exposure to cold, or eating a large meal.</li><li>The long-term course of angina.</li><li>Information on how angina is managed.</li></ul></li><li>Encourage the person to ask questions about their angina and its management.</li><li>Explore and address any misconceptions the person might have about their angina. This includes:<ul><li>Implications for daily activities.</li><li>Risk of myocardial infarction.</li><li>Life expectancy.</li></ul></li><li>Advise the person to seek medical help if there is a sudden worsening in the frequency or severity of their angina.</li><li>Discuss the reasons for treatment, as well as the benefits and adverse effects (such as flushing, headache, and light-headedness). For more information, see the section on <a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/\">Prescribing information</a>.<ul><li>Provide information on how to use a short-acting sublingual nitrate and when to administer it. </li></ul></li><li>Assess the person's need for lifestyle advice to manage their <a class=\"topic-reference internal-reference\" href=\"/topics/angina/background-information/risk-factors/\">cardiovascular risk</a>.</li><li>Explore and address issues according to the person's needs, which may include:<ul><li>Self-management skills such as pacing their activities and goal setting.</li><li>Concerns about the impact of stress, anxiety, or depression on angina.</li><li>Advice about physical exertion including <a class=\"topic-reference internal-reference\" href=\"/topics/angina/management/new-diagnosis/#advice-on-sexual-activity\">sexual activity</a>.</li><li>Advice about other activities such as <a class=\"topic-reference internal-reference\" href=\"/topics/angina/management/new-diagnosis/#advice-on-driving\">driving</a>, <a class=\"topic-reference internal-reference\" href=\"/topics/angina/management/new-diagnosis/#advice-on-flying\">flying</a>, and <a class=\"topic-reference internal-reference\" href=\"/topics/angina/management/new-diagnosis/#advice-on-work\">work</a>.</li></ul></li><li>Advise people that the aim of <a class=\"topic-reference internal-reference\" href=\"/topics/angina/management/new-diagnosis/#drug-treatment\">anti-anginal drug treatment</a> is to prevent episodes of angina and the aim of secondary prevention treatment is to prevent cardiovascular events such as heart attack and stroke.</li></ul></li></ul><!-- end field 63210e39-f9a0-4622-ba88-8fec016fc719 --><!-- end item cd656055-1c39-4b07-a1c7-2ba25e28af4b -->","subChapters":[{"id":"f40045cf-4901-5b45-8a73-38d244d7e944","slug":"basis-for-recommendation-284","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 273d79b1-bd76-4ad2-8eef-4fcb59423d68 --><h4>Basis for recommendation</h4><!-- end field 273d79b1-bd76-4ad2-8eef-4fcb59423d68 -->","summary":null,"htmlStringContent":"<!-- begin item 284a602b-eb99-4bb7-867b-3941755508ff --><!-- begin field bf801bd8-287c-4934-81a2-74782d87ac8a --><p>These recommendations are based on the National Institute of Health and Care Excellence (NICE) guideline <em>Stable angina: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2016b</a>].</p><!-- end field bf801bd8-287c-4934-81a2-74782d87ac8a --><!-- end item 284a602b-eb99-4bb7-867b-3941755508ff -->","subChapters":[]}]},{"id":"ea654701-cfb9-57a5-99fa-166130831941","slug":"drug-treatment","fullItemName":"Drug treatment","depth":3,"htmlHeader":"<!-- begin field e26be7c6-fac9-459d-a0a2-c6327c320990 --><h3>What drug treatments should I prescribe for a person with stable angina?</h3><!-- end field e26be7c6-fac9-459d-a0a2-c6327c320990 -->","summary":null,"htmlStringContent":"<!-- begin item dc10c7cc-f985-4912-96f1-d25fa7bf9df5 --><!-- begin field b58d5729-547e-411a-ba22-8fbf64880b80 --><ul><li><strong>Drug treatment for symptom relief:</strong><ul><li><strong>Prescribe <a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/nitrates/\">sublingual glyceryl trinitrate</a> (GTN) for the rapid relief of symptoms of angina </strong>and for use before performing activities known to cause symptoms of angina.</li><li>Instruct the person that if they experience chest pain they should:<ul><li>Stop what they are doing and rest.</li><li>Use their glyceryl trinitrate spray or tablets as instructed.</li><li>Take a second dose after 5 minutes if the pain has not eased.</li><li>Call 999 for an ambulance if the pain has not eased 5 minutes after the second dose, or earlier if the pain is intensifying or the person is unwell.</li></ul></li><li><strong>Prescribe a <a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/beta-blockers/\">beta-blocker</a> or a <a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/calcium-channel-blockers/\">calcium-channel blocker</a> (CCB) as first-line regular treatment </strong>to reduce the symptoms of stable angina, depending on the person's co-morbidities, contraindications, the person's preference. <ul><li>If the person cannot tolerate the beta blocker or calcium channel blocker, consider switching to the other option (calcium channel blocker or beta blocker).</li></ul></li><li><strong>If both beta-blockers and CCBs are <a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/beta-blockers/#cautions-contraindications\">contraindicated</a> or not tolerated, </strong>consider monotherapy with <em>one </em>of the following drugs. Decide which drug to use based on co-morbidities, contraindications, the person's preference, and cost:<ul><li>A long-acting <a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/nitrates/\">nitrate</a> (such as isosorbide mononitrate).</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/nicorandil/\">Nicorandil</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/ivabradine/\">Ivabradine</a>.</li><li><a class=\"topic-reference internal-reference\" href=\"/topics/angina/prescribing-information/ranolazine/\">Ranolazine</a>.</li></ul></li><li><strong>Review response to treatment, </strong>including any adverse effects, 2–4 weeks after starting or changing drug treatment.<ul><li>Titrate the dose against symptoms up to the maximum licensed or tolerated dose.</li><li>If there is a poor response to treatment, see the scenario <a class=\"topic-reference internal-reference\" href=\"/topics/angina/management/poor-control-on-treatment/\">Poor control on treatment</a>.</li></ul></li></ul></li><li><strong>Drug treatment for secondary prevention:</strong><ul><li><strong>Consider antiplatelet treatment in all people with stable angina, </strong>taking into account the person's risk of bleeding and co-morbidities.<ul><li>For most people this will be low-dose aspirin (75 mg daily) — people with stroke or peripheral arterial disease should already be taking clopidogrel rather than aspirin, and should continue taking clopidogrel.</li><li>For information on antiplatelet prophylaxis, including advice on what to do if the person is allergic to aspirin or is at risk of gastrointestinal adverse effects, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/antiplatelet-treatment/\">Antiplatelet treatment</a>.</li></ul></li><li><strong>Consider treatment with an angiotensin-converting enzyme (ACE) inhibitor </strong>for people with stable angina and diabetes mellitus.<ul><li>Ensure that people with coexisting hypertension, heart failure, asymptomatic left ventricular dysfunction, chronic kidney disease, or previous myocardial infarction have been prescribed an ACE inhibitor in line with current guidance unless this is contraindicated or not tolerated.</li><li>For more information, see the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>, <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>, and <a class=\"topic-reference external-reference\" href=\"/topics/mi-secondary-prevention/\">MI - secondary prevention</a>.</li></ul></li><li>Offer a statin. For further information see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/lipid-modification-cvd-prevention/\">Lipid modification - CVD prevention</a>.</li><li>Offer antihypertensive treatment. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>.</li></ul></li></ul><!-- end field b58d5729-547e-411a-ba22-8fbf64880b80 --><!-- end item dc10c7cc-f985-4912-96f1-d25fa7bf9df5 -->","subChapters":[{"id":"febfd1f3-eaef-5709-b790-3058a17acfff","slug":"basis-for-recommendation-998","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 0444fcda-7d22-453b-9792-28cefd31bd65 --><h4>Basis for recommendation</h4><!-- end field 0444fcda-7d22-453b-9792-28cefd31bd65 -->","summary":null,"htmlStringContent":"<!-- begin item 9987b8fa-cb22-4691-9a38-44aca198a747 --><!-- begin field 28931845-57fa-47c8-a4b8-b1a37cbe33e0 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guideline <em>Stable angina: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2016b</a>]<em> and a </em>Medicines and Healthcare products Regulatory Agency (MHRA) <em>Drug safety update</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">MHRA, 2016</a>].</p><ul><li><strong>Use of sublingual glyceryl trinitrate</strong><ul><li>NICE recommends calling an amulance if a second dose of GTN does not relieve angina symptoms within 5 minutes. However, the manufacturers of Nitrolingual Pump Spray<sup>®</sup> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016a</a>] and glyceryl trinitrate tablets [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2016b</a>] recommend seeking prompt medical attention if symptoms are not relieved after three doses. </li></ul></li><li><strong>Nicorandil as monotherapy</strong><ul><li>Nicorandil should only be used to treat stable angina in people whose angina is inadequately controlled by first line anti-anginal therapies, or who have a contraindication or intolerance to first line anti-anginal therapies, such as beta-blockers or calcium antagonists, because of the risk of ulcer complications [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">MHRA, 2016</a>].</li></ul></li><li><strong>Choice between second-line drug treatments</strong><ul><li>There is insufficient evidence to recommend one second-line treatment over another if a beta-blocker and a calcium-channel blocker (CCB) are both contraindicated, or not tolerated [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2016b</a>].<ul></ul></li></ul></li></ul><!-- end field 28931845-57fa-47c8-a4b8-b1a37cbe33e0 --><!-- end item 9987b8fa-cb22-4691-9a38-44aca198a747 -->","subChapters":[]}]},{"id":"04fcd2d4-2349-54e5-9b4b-1e1dae3ede3f","slug":"referral","fullItemName":"Referral","depth":3,"htmlHeader":"<!-- begin field 4270905f-64de-49b0-8e5c-c5c1c5840cce --><h3>When should I refer a person with newly diagnosed angina? </h3><!-- end field 4270905f-64de-49b0-8e5c-c5c1c5840cce -->","summary":null,"htmlStringContent":"<!-- begin item eda105d3-43b9-460a-b95b-29ee36974270 --><!-- begin field c4da9de7-791a-48c2-bfc0-33072b59e2e9 --><ul><li><strong>Consider hospital admission for people with the following symptoms, as they may have unstable angina:</strong><ul><li>Pain at rest (which may occur at night).</li><li>Pain on minimal exertion.</li><li>Angina that seems to be progressing rapidly despite increasing medical treatment.</li></ul></li><li><strong>Indications for early referral to a cardiologist include:</strong><ul><li>Previous myocardial infarction, coronary artery bypass graft, or percutaneous transluminal coronary angioplasty and development of angina.</li><li>ECG (electrocardiographic) evidence of previous myocardial infarction or other significant abnormality.</li><li>Newly diagnosed atrial fibrillation and angina.</li><li>Heart failure and angina.</li><li>An ejection systolic murmur suggesting aortic stenosis.</li><li>Any suggestion of hypertrophic cardiomyopathy (for example by family history, physical examination, or ECG).</li></ul></li><li><strong>Further reasons to refer people to a cardiologist include:</strong><ul><li>Doubt about the diagnosis.</li><li>The presence of several risk factors or a strong family history.</li><li>The person's preference for referral.</li></ul></li></ul><!-- end field c4da9de7-791a-48c2-bfc0-33072b59e2e9 --><!-- end item eda105d3-43b9-460a-b95b-29ee36974270 -->","subChapters":[{"id":"49f288dc-1124-5492-ade4-6c17b16523c2","slug":"basis-for-recommendation-fdf","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 1db19c42-ba80-4863-bf98-949c012822a5 --><h4>Basis for recommendation</h4><!-- end field 1db19c42-ba80-4863-bf98-949c012822a5 -->","summary":null,"htmlStringContent":"<!-- begin item fdf66ac0-26a8-47be-8383-436dac153a8b --><!-- begin field 5a0f1dfe-2875-4190-89f8-dfdbad563fd1 --><p>These recommendations are based on the Scottish Intercollegiate Guidelines Network (SIGN) guideline <em>Management of stable angina</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">SIGN, 2007</a>], and the National Institute for Health and Care Excellence (NICE) guideline <em>Stable angina: management</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2016a</a>].</p><!-- end field 5a0f1dfe-2875-4190-89f8-dfdbad563fd1 --><!-- end item fdf66ac0-26a8-47be-8383-436dac153a8b -->","subChapters":[]}]},{"id":"f1e070e0-be20-534f-a7a2-d1a36ea7d993","slug":"managing-cardiovascular-risk","fullItemName":"Managing cardiovascular risk","depth":3,"htmlHeader":"<!-- begin field 12222524-00a8-4c78-abec-c45e89583c0d --><h3>How should I manage the cardiovascular risk in a person with angina?</h3><!-- end field 12222524-00a8-4c78-abec-c45e89583c0d -->","summary":null,"htmlStringContent":"<!-- begin item fd753752-1e28-4c23-a129-5cbc95311446 --><!-- begin field c5760ad3-78bf-46b5-aa53-0237d6f35088 --><p>All people with angina are assumed to be at high risk for cardiovascular events, and their cardiovascular risk factors should be managed accordingly.</p><ul><li><strong>Optimize the management of comorbid conditions that present an increased risk of cardiovascular events, </strong>such <a class=\"topic-reference external-reference\" href=\"/topics/atrial-fibrillation/\">Atrial fibrillation</a>, <a class=\"topic-reference external-reference\" href=\"/topics/chronic-kidney-disease/\">Chronic kidney disease</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-1/\">Diabetes - type 1</a>, <a class=\"topic-reference external-reference\" href=\"/topics/diabetes-type-2/\">Diabetes - type 2</a>, <a class=\"topic-reference external-reference\" href=\"/topics/heart-failure-chronic/\">Heart failure - chronic</a>, <a class=\"topic-reference external-reference\" href=\"/topics/hypertension-not-diabetic/\">Hypertension - not diabetic</a>, <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>, <a class=\"topic-reference external-reference\" href=\"/topics/rheumatoid-arthritis/\">Rheumatoid arthritis</a> and <a class=\"topic-reference external-reference\" href=\"/topics/stroke-tia/\">Stroke and TIA</a>.</li><li><strong>Advise and assist all people who smoke to stop. </strong>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/smoking-cessation/\">Smoking cessation</a>.</li><li><strong>Encourage people to eat a cardioprotective diet. </strong>For more information, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/mi-secondary-prevention/management/secondary-prevention/\">Secondary prevention</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/mi-secondary-prevention/\">MI - secondary prevention</a>.<ul><li>Do not offer vitamin or fish oil supplements to treat stable angina — inform people that there is no evidence that they help stable angina.</li></ul></li><li><strong>Offer advice and support to achieve and maintain a healthy weight </strong>to people who are overweight or obese. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/obesity/\">Obesity</a>.</li><li><strong>Encourage people to increase their physical activity levels within the limits set by their symptoms. </strong>For more information on the recommended levels of physical activity for cardiovascular protection, see the section on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/management/cvd-risk-less-than-10percent/#lifestyle-advice\">Lifestyle advice</a> in the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/cvd-risk-assessment-management/\">CVD risk assessment and management</a>.</li><li><strong>Encourage people to limit their alcohol consumption.</strong><ul><li>Advise men and women to limit their alcohol intake to 14 units a week and to spread this evenly over three days or more. </li><li>For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/alcohol-problem-drinking/\">Alcohol - problem drinking</a>.</li></ul></li></ul><!-- end field c5760ad3-78bf-46b5-aa53-0237d6f35088 --><!-- end item fd753752-1e28-4c23-a129-5cbc95311446 -->","subChapters":[{"id":"2ce9c200-20e8-5a66-ac0c-d2051b7c749a","slug":"basis-for-recommendation-bdf","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 895d8025-f010-468c-be2d-f4b4dfe10ecc --><h4>Basis for recommendation</h4><!-- end field 895d8025-f010-468c-be2d-f4b4dfe10ecc -->","summary":null,"htmlStringContent":"<!-- begin item bdf4a4ac-2a2e-4954-8fd4-24947cc10e0b --><!-- begin field 3b6fb8e9-ed95-4a90-9f1c-bb1d5eb86ac4 --><p>These recommendations are based on the National Institute for Health and Care Excellence (NICE) guidelines <em>Cardiovascular disease: risk assessment and reduction, including lipid modification </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2016c</a>]<em>, </em><em>Stable angina: management </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">NICE, 2016b</a>] and the <em>Alcohol guidelines review: report from the guidelines development group to the UK Chief Medical Officers</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">DH, 2016</a>].</p><!-- end field 3b6fb8e9-ed95-4a90-9f1c-bb1d5eb86ac4 --><!-- end item bdf4a4ac-2a2e-4954-8fd4-24947cc10e0b -->","subChapters":[]}]},{"id":"7c6caeb2-eeba-5686-b757-87d0ac5497b2","slug":"advice-on-work","fullItemName":"Advice on work","depth":3,"htmlHeader":"<!-- begin field fdc8b664-7f9e-4630-acdb-a7237910daea --><h3>What advice should I give about work?</h3><!-- end field fdc8b664-7f9e-4630-acdb-a7237910daea -->","summary":null,"htmlStringContent":"<!-- begin item ae7fb76c-3795-47b5-a3ae-3ece850f773a --><!-- begin field ca91ed70-32fb-41e6-bac9-ef4b04345552 --><ul><li>Advise people with angina that:<ul><li>Many people with angina can continue to work as before.</li><li>If their job involves heavy manual work, they may need to alter their work practices.</li><li>If their job involves <a class=\"topic-reference internal-reference\" href=\"/topics/angina/management/new-diagnosis/#advice-on-driving\">driving</a>, they should consult the Driver and Vehicle Licensing Agency (DVLA).</li></ul></li><li>If the person's employer has an occupational health department, they should be encouraged to discuss any issues with them.</li><li>Further information is available from the <a href=\"http://www.bhf.org.uk/\" data-hyperlink-id=\"80763bef-ceca-4517-b234-a993008f6286\">British Heart Foundation (BHF</a>) which produces the booklets <a href=\"https://www.bhf.org.uk/publications/heart-conditions/returning-to-work-with-a-heart-condition\" data-hyperlink-id=\"c12086b2-47b0-413f-8ea8-a993008f634f\">Returning to work with a heart condition</a> and <a href=\"https://www.bhf.org.uk/publications/heart-conditions/angina\" data-hyperlink-id=\"cbd4e666-32cb-4fe7-9d9c-a993008f6429\">Angina</a>.</li></ul><!-- end field ca91ed70-32fb-41e6-bac9-ef4b04345552 --><!-- end item ae7fb76c-3795-47b5-a3ae-3ece850f773a -->","subChapters":[{"id":"1b44067d-0079-5ccc-ae48-d43b9a6ac971","slug":"basis-for-recommendation-851","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 17f8312c-9ec9-469e-9286-656e897b4dfe --><h4>Basis for recommendation</h4><!-- end field 17f8312c-9ec9-469e-9286-656e897b4dfe -->","summary":null,"htmlStringContent":"<!-- begin item 8510bebc-da58-4f67-932f-9aef9fea78a2 --><!-- begin field d6f91cdc-3150-47a8-acef-e201e56d8b50 --><p>This information is based on the British Heart Foundation (BHF) booklets <em>Returning to work with a heart condition</em>  [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BHF, 2014a</a>] and <em>Angina</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BHF, 2014b</a>].</p><!-- end field d6f91cdc-3150-47a8-acef-e201e56d8b50 --><!-- end item 8510bebc-da58-4f67-932f-9aef9fea78a2 -->","subChapters":[]}]},{"id":"b7e0ab73-4b57-5c9d-88e0-16956e639442","slug":"advice-on-driving","fullItemName":"Advice on driving","depth":3,"htmlHeader":"<!-- begin field 85d9eb65-4548-4938-ab57-48e83a676c54 --><h3>What advice should I give about driving?</h3><!-- end field 85d9eb65-4548-4938-ab57-48e83a676c54 -->","summary":null,"htmlStringContent":"<!-- begin item 62281f1c-8bbe-4b0a-ad4b-862dd8a0ac26 --><!-- begin field 1ff51651-d945-4266-aeb1-f9e6948315e2 --><ul><li>Advise the person that it is their responsibility to inform the Driver and Vehicle Licensing Agency (DVLA) of any condition that may affect their ability to drive.</li><li>The DVLA's medical rules regarding angina are:<ul><li><strong>For group 1 entitlement (cars, motorcycles):</strong><ul><li>Driving must cease when symptoms occur at rest, with emotion, or whilst driving.</li><li>Driving may recommence when satisfactory symptom control is achieved.</li><li>The DVLA need not be notified.</li></ul></li><li><strong>For group 2 entitlement (lorries, buses):</strong><ul><li>Must not drive and must notify the DVLA when symptoms occur.</li><li>Refusal or revocation of a driver's licence may occur if symptoms (treated or untreated) continue.</li><li>Re-licensing may be permitted thereafter, provided that the person has been free from angina for at least 6 weeks, exercise or other functional test requirements can be met, and there is no other disqualifying condition.</li></ul></li></ul></li><li>The person should check with their insurer to ensure that their insurance cover is appropriate with a diagnosis of angina.</li></ul><!-- end field 1ff51651-d945-4266-aeb1-f9e6948315e2 --><!-- end item 62281f1c-8bbe-4b0a-ad4b-862dd8a0ac26 -->","subChapters":[{"id":"57b6366a-225d-5620-a8eb-1decc91a570a","slug":"basis-for-recommendation-5d4","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3f10fcb4-04b8-45a4-9084-82fe32e89348 --><h4>Basis for recommendation</h4><!-- end field 3f10fcb4-04b8-45a4-9084-82fe32e89348 -->","summary":null,"htmlStringContent":"<!-- begin item 5d4a9f4e-e0f1-4573-9b31-f73335d5d0b2 --><!-- begin field 8147b784-2af8-4037-a040-454fa1d4f430 --><p>These recommendations are based on the Driver and Vehicle Licensing Agency (DVLA) guidance <em>Assessing fitness to drive - a guide for medical professionals</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">DVLA, 2016</a>]<em>.</em></p><!-- end field 8147b784-2af8-4037-a040-454fa1d4f430 --><!-- end item 5d4a9f4e-e0f1-4573-9b31-f73335d5d0b2 -->","subChapters":[]}]},{"id":"948535d7-ed84-598c-9adb-f772902d875b","slug":"advice-on-sexual-activity","fullItemName":"Advice on sexual activity","depth":3,"htmlHeader":"<!-- begin field 6b2bacf9-6914-44ea-9abe-79c883a787a7 --><h3>What advice should I give about sexual activity?</h3><!-- end field 6b2bacf9-6914-44ea-9abe-79c883a787a7 -->","summary":null,"htmlStringContent":"<!-- begin item 4227e474-505c-4a9e-be05-c967809db8e9 --><!-- begin field 23a59f5e-5934-47a2-9843-0aa5869e6fbc --><ul><li>Advise the person that many people with angina continue to enjoy sexual intercourse, and that it is just as safe as other equally energetic forms of exercise.</li><li>If sexual activity does precipitate an episode of angina, sublingual glyceryl trinitrate (GTN) taken immediately before intercourse may help prevent subsequent attacks.</li><li>The concomitant use of nitrates or nicorandil with phosphodiesterase inhibitors (sildenafil, tadalafil, and vardenafil), often used in the treatment of erectile dysfunction, is contraindicated.</li><li>Advise people with angina who take a phosphodiesterase inhibitor that:<ul><li>A nitrate should not be taken for at least 24 hours after the last dose of sildenafil or vardenafil, and for at least 48 hours after the last dose of tadalafil. </li><li>A phosphodiesterase inhibitor should not be taken for at least 24 hours after the last dose of a nitrate.</li><li>If they have an episode of angina during sexual intercourse, they must not use glyceryl trinitrate (GTN). They should stop sexual activity and, if their pain does not resolve within 10 minutes, they should call 999 for an ambulance.</li></ul></li></ul><!-- end field 23a59f5e-5934-47a2-9843-0aa5869e6fbc --><!-- end item 4227e474-505c-4a9e-be05-c967809db8e9 -->","subChapters":[{"id":"1ebe39a6-a917-5ff8-87b3-43a9bdbfe22a","slug":"basis-for-recommendation-cfd","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 3ce58f0b-a37d-4408-afd1-c326bae41107 --><h4>Basis for recommendation</h4><!-- end field 3ce58f0b-a37d-4408-afd1-c326bae41107 -->","summary":null,"htmlStringContent":"<!-- begin item cfd81dc4-5849-430b-8a11-cca428a62c63 --><!-- begin field 5ebcc553-b9bc-4674-9796-e1da2027918e --><p>These recommendations are based on the British Heart Foundation (BHF) booklet <em>Angina </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BHF, 2014b</a>], a medical textbook [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">Baxter, 2013</a>], and the manufacturers' Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">ABPI, 2015</a>].</p><!-- end field 5ebcc553-b9bc-4674-9796-e1da2027918e --><!-- end item cfd81dc4-5849-430b-8a11-cca428a62c63 -->","subChapters":[]}]},{"id":"34acfc5b-278b-586f-94ec-21033f7f8a63","slug":"advice-on-flying","fullItemName":"Advice on flying","depth":3,"htmlHeader":"<!-- begin field 6e13bb86-3e19-496a-b17a-bec22d12b7ce --><h3>What advice should I give about air travel? </h3><!-- end field 6e13bb86-3e19-496a-b17a-bec22d12b7ce -->","summary":null,"htmlStringContent":"<!-- begin item fe09e658-fb71-45e7-88ea-d0598bb002f3 --><!-- begin field 540b5e9d-909b-479e-8424-574ebc036110 --><ul><li>Give the person the following advice depending on the severity of their angina symptoms:<ul><li>Chest pain on considerable exertion with no recent change in symptoms or medication — no restriction on air travel.</li><li>Chest pain on minimal exertion with no recent change of symptoms or medication — consider airport assistance and possible in-flight oxygen.</li><li>Chest pain at rest or a change in symptoms and/or medication — defer travel until stable, or travel with a medical escort and ensure in-flight oxygen is available.</li></ul></li></ul><!-- end field 540b5e9d-909b-479e-8424-574ebc036110 --><!-- end item fe09e658-fb71-45e7-88ea-d0598bb002f3 -->","subChapters":[{"id":"173a5bb7-23a6-58c9-88b1-3c877571aab4","slug":"basis-for-recommendation-f5d","fullItemName":"Basis for recommendation","depth":4,"htmlHeader":"<!-- begin field 7d83b42c-56ba-4ac9-a18f-8053036e8a17 --><h4>Basis for recommendation</h4><!-- end field 7d83b42c-56ba-4ac9-a18f-8053036e8a17 -->","summary":null,"htmlStringContent":"<!-- begin item f5de89cb-f851-4c9e-aba3-6da3174f2709 --><!-- begin field 6a11b231-6b83-4bde-9e7e-2d2b1c804250 --><p>These recommendations are based on the British Cardiovascular Society (BCS) guidance <em>Fitness to fly for passengers with cardiovascular disease</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/angina/references/\">BCS, 2010</a>]. </p><!-- end field 6a11b231-6b83-4bde-9e7e-2d2b1c804250 --><!-- end item f5de89cb-f851-4c9e-aba3-6da3174f2709 -->","subChapters":[]}]}]}}},"staticQueryHashes":["3666801979"]}